618 related articles for article (PubMed ID: 15191675)
1. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
2. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
[TBL] [Abstract][Full Text] [Related]
3. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
[TBL] [Abstract][Full Text] [Related]
4. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
5. [Measurement and analysis of different serum PSA in patients with benign prostatic hyperplasia].
Li Y; Xu P; Zhang PA; Su HW; Zhang J
Zhonghua Nan Ke Xue; 2003 Aug; 9(5):361-3, 366. PubMed ID: 14513646
[TBL] [Abstract][Full Text] [Related]
6. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma.
Froschermaier SE; Pilarsky CP; Wirth MP
Urology; 1996 Apr; 47(4):525-8. PubMed ID: 8638361
[TBL] [Abstract][Full Text] [Related]
8. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
9. Effect of NIH-IV prostatitis on free and free-to-total PSA.
Stancik I; Lüftenegger W; Klimpfinger M; Müller MM; Hoeltl W
Eur Urol; 2004 Dec; 46(6):760-4. PubMed ID: 15548444
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer].
Fu Q; Yao DH; Jiang YQ
Zhonghua Nan Ke Xue; 2002 Dec; 8(6):411-3. PubMed ID: 12593013
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of prostatic-specific antigen levels in patients with benign prostatic hyperplasia complicated by low urinary tract syndrome].
Zhu YJ; Ye M; Wang WM; Shen HB; Chen JH; Chen F
Zhonghua Nan Ke Xue; 2006 Feb; 12(2):156-8. PubMed ID: 16519156
[TBL] [Abstract][Full Text] [Related]
12. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
[TBL] [Abstract][Full Text] [Related]
13. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C
Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
[TBL] [Abstract][Full Text] [Related]
15. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Stephan C; Lein M; Jung K; Schnorr D; Loening SA
Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
[TBL] [Abstract][Full Text] [Related]
16. [Aggressiveness and extent of prostatic inflammation relates with serum PSA levels in type IV prostatitis].
Man LB; Li GZ; Huang GL; Wang JW; Liu BY
Zhonghua Nan Ke Xue; 2012 Aug; 18(8):710-4. PubMed ID: 22934516
[TBL] [Abstract][Full Text] [Related]
17. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
18. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
[TBL] [Abstract][Full Text] [Related]
19. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
[TBL] [Abstract][Full Text] [Related]
20. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network.
Stephan C; Xu C; Brown DA; Breit SN; Michael A; Nakamura T; Diamandis EP; Meyer H; Cammann H; Jung K
Prostate; 2006 May; 66(6):651-9. PubMed ID: 16388506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]